Celltrion Files For Korea Approval Of Herceptin Biosimilar
This article was originally published in PharmAsia News
Executive Summary
Amid M&A talks and expectations for imminent European approval of a Remicade biosimilar, Celltrion becomes the first company to file for regulatory approval of a biosimilar of Roche’s blockbuster breast cancer therapy trastuzumab.